Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.65 |
| ▸ | BRD4 | O60885 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.55 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.47 |
| ▸ | LOX | P28300 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1228349 | 0.87 | CYP2C9 (0.58) | PSIP1BRD4CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL644484 | 0.85 | MEN1 (0.53) | PSIP1BRD4CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2704870 | 0.84 | CYP2C9 (0.49) | PSIP1BRD4CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2703373 | 0.83 | CYP2C9 (0.48) | PSIP1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL17263850 | 0.83 | PSIP1 (0.68) | PSIP1BRD4CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2705059 | 0.82 | LARS1 (0.51) | PSIP1BRD4CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4630948 | 0.81 | CYP2C9 (0.47) | PSIP1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL293991 | 0.81 | PSIP1 (0.74) | PSIP1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5134257 | 0.81 | PSIP1 (0.74) | PSIP1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL180713 | 0.80 | PSIP1 (1.00) | PSIP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20110135604-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| EP-1919907-A2 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | PSIP1 3985/4885BRD4 864/4885CYP1A2 486/4885 |
| US-20110135604-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | PSIP1 1500/4885BRD4 1594/4885CYP1A2 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.